Prof. Dr. Can’s team focused on precisely these strains. Their newly developed diagnostic system identifies, in a single and rapid test, the genetic markers responsible for both pathogenicity and antibiotic resistance. Until now, these features could only be assessed separately, often through time-consuming procedures that delayed effective treatment. The ability to capture this critical information simultaneously represents a significant advance in molecular diagnostics.
New Diagnostic Approach Targets Dangerous Klebsiella Strains
Unlike viral outbreaks, bacterial resistance does not erupt suddenly – but its cumulative impact is profound. Delayed or inappropriate antibiotic treatment increases mortality risk, prolongs hospital stays, and accelerates the spread of resistant strains. Rapid, accurate diagnosis is therefore central to effective clinical decision-making. By enabling clinicians to identify the most dangerous Klebsiella strains at an early stage, this new approach supports timely, targeted therapy and strengthens infection-control strategies in healthcare settings.
Recognition for Innovative Research in Molecular Diagnostics
The Nature MDx Impact Award is presented to research that not only advances diagnostic science but also addresses urgent clinical needs. In its evaluation, Nature highlighted the project’s originality, translational relevance, and potential for broad implementation. The study’s selection underscores the growing importance of molecular epidemiology and precision diagnostics in confronting the global antibiotic resistance crisis. The project is supported by international industry collaboration, further strengthening its pathway toward clinical application.
Unraveling Klebsiella’s Immune Evasion for Future Therapies
Beyond diagnostics, Prof. Dr. Can’s research program aims to unravel how Klebsiella pneumoniae evades the immune system – a key step toward developing next-generation treatment strategies. Understanding these mechanisms could enable the design of novel therapeutic molecules, potentially supported by artificial intelligence–driven drug discovery.
As antibiotic resistance continues to challenge healthcare systems worldwide, this work offers a timely and concrete step forward, the researchers state – transforming molecular insight into tools that can save lives.
Source: Koç University